Curaleaf Holdings, Inc. (OTCMKTS:CURLF – Free Report) – Equities research analysts at Alliance Global Partners lowered their Q1 2025 earnings estimates for shares of Curaleaf in a research report issued to clients and investors on Tuesday, March 4th. Alliance Global Partners analyst A. Grey now forecasts that the company will earn ($0.08) per share for the quarter, down from their previous forecast of ($0.07). The consensus estimate for Curaleaf’s current full-year earnings is ($0.25) per share. Alliance Global Partners also issued estimates for Curaleaf’s Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.30) EPS and FY2026 earnings at ($0.23) EPS.
Curaleaf (OTCMKTS:CURLF – Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.09. Curaleaf had a negative net margin of 14.82% and a negative return on equity of 13.67%. The company had revenue of $331.05 million for the quarter, compared to the consensus estimate of $331.87 million.
Read Our Latest Report on Curaleaf
Curaleaf Price Performance
Curaleaf stock opened at $1.11 on Thursday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.51 and a current ratio of 1.11. Curaleaf has a 1 year low of $0.88 and a 1 year high of $6.40. The firm has a 50 day moving average price of $1.44 and a 200 day moving average price of $2.18. The company has a market cap of $733.29 million, a price-to-earnings ratio of -3.83 and a beta of 0.57.
About Curaleaf
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
See Also
- Five stocks we like better than Curaleaf
- What is a support level?
- Broaden Your ETF Exposure With These 3 Overlooked Funds
- Roth IRA Calculator: Calculate Your Potential Returns
- 2 Stocks Insiders Are Buying and 1 They’re Selling
- How to Profit From Growth Investing
- 2 Must-Have Stocks as Consumers Prioritize Needs Over Wants
Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.